BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Regarding the p38MAPK signaling pathway it has been reported to have a central role in BCR/ABL associated transformation [29], [30] as well as in the resistance to other antitumoral agents used in CML [3], [31].